Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus

Mayo Clinic Proceedings

Volumn 78, Issue 4, 2003, Pages 447-456

  Gerich, John E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

DIABETIC MICROANGIOPATHY; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HEREDITY; HIGH RISK POPULATION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS ISLET BETA CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; REVIEW;

EID: 0037382455     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.4.447     Document Type: Review

References (121)

1. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association: clinical practice recommendations 2002. Diabetes Care. 2002;25(suppl 1):S1-S147.
3. Kahn BB. Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance. Cell. 1998;92:593-596.
4. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999;22:345-354.
5. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
7. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1557]. Lancet. 1998;352:854-865.
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
9. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management-2000 update. Endocr Pract. 2000;6:43-84.
10. Shorr RI, Franse LV, Resnick HE, Di Bari M, Johnson KC, Pahor M. Glycemic control of older adults with type 2 diabetes: findings from the Third National Health and Nutrition Examination Survey, 1988-1994. J Am Geriatr Soc. 2000;48:264-267.
11. Gerich JE. Is insulin resistance the principal cause of type 2 diabetes? Diabetes Obes Metab. 1999;1:257-263.
12. Gerich JE. Role of insulin resistance in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus. Baillieres Clin Endocrinol Metab. 1988;2:307-326.
13. O'Rahilly S, Hattersley A, Vaag A, Gray H. Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? Lancet. 1994;344:585-589.
14. Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia. 1995;38: 992-997.
15. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev. 1998;19:477-490.
16. Wilson JD, Foster DW. Williams Textbook of Endocrinology. 7th ed. Philadelphia, Pa: WB Saunders Co; 1985.
17. Woods SC, Seeley RJ, Porte D Jr, Schwartz MW, Signals that regulate food intake and energy homeostasis. Science, 1998;280:1378-1383.
18. American Diabetes Association. Consensus Development Conference on Insulin Resistance: 5-6 November 1997. Diabetes Care. 1998;21:310-314.
19. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46:1954-1962.
20. Arner P, Pollare T, Lithell H. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia. 1991;34:483-487.
21. Boden G, Chen X, Polansky M. Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes. Diabetes. 1999;48:2182-2188.
22. Nesher R, Della Casa L, Litvin Y, et al. Insulin deficiency and insulin resistance in type 2 (non-insulin-dependent) diabetes: quantitative contributions of pancreatic and peripheral responses to glucose homeostasis. Eur J Clin Invest. 1987;17:266-274.
23. Pigon J, Giacca A, Ostenson CG, Lam L, Vranic M, Efendic S. Normal hepatic insulin sensitivity in lean, mild noninsulin-dependent diabetic patients. J Clin Endocrinol Metab. 1996;81:3702-3708.
24. Polonsky KS, Evolution of β-cell dysfunction in impaired glucose tolerance and diabetes. Exp Clin Endocrinol Diabetes. 1999;107(suppl 4):S124-S127.
25. Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;95:690-698.
26. Byme MM, Sturis J, Sobel RJ, Polonsky KS. Elevated plasma glucose 2 h postchallenge predicts defects in β-cell function. Am J Physiol. 1996;270(4, pt 1):E572-E579.
27. Elbein SC, Hasstedt SJ, Wegner K, Kahn SE. Heritability of pancreatic β-cell function among nondiabetic members of caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab. 1999;84:1398-1403,
28. Elbein SC, Wegner K, Kahn SE. Reduced β-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. Diabetes Care. 2000;23:221-227.
29. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989;321:337-343.
30. Haffner SM, Miettinen H, Gaskill SP, Stem MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes. 1995;44:1386-1391.
31. Henriksen JE, Alford F, Ward GM, Beck-Nielsen H. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia. 1997;40:1439-1448.
32. Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic betacell dysfunction as the primary genetic lesion in NIDDM: evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA. 1995;273:1855-1861.
33. van Haeften TW, Dubbeldam S, Zonderland ML, Erkelens DW. Insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects: assessments using hyperglycemic glucose clamps and oral glucose tolerance tests. Diabetes Care. 1998;21:278-282.
34. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care. 2001;24:89-94.
35. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473-481.
36. Bloomgarden ZT. Insulin resistance: current concepts. Clin Ther. 1998;20:216-231.
37. Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab. 1999;1(suppl 1):S1-S7.
38. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res. 2001;56:265-294.
39. Reaven GM. Insulin resistance: a chicken that has come to roost. Ann N Y Acad Sci. 1999;892:45-57.
40. Whitelaw DC, Gilbey SG. Insulin resistance. Ann Clin Biochem. 1998;35(pt 5):567-583.
41. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel HI). JAMA. 2001;285:2486-2497.
42. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-359.
43. Reusch JE. Focus on insulin resistance in type 2 diabetes: therapeutic implications. Diabetes Educ. 1998;24:188-193.
44. Saltiel AR. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell. 2001;104:517-529.
45. Haffner SM, Howard G, Mayer E, et al. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes. 1997;46:63-69.
46. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med. 1993;329:1988-1992.
47. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992;340:925-929.
48. Gulli G, Ferrannini E, Stem M, Haffner S, DeFronzo RA. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes. 1992;41:1575-1586.
49. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113:909-915.
50. Lillioja S, Mott DM, Howard BV, et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med. 1988;318:1217-1225.
51. Gerich J. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev. 1998;19:491-503.
52. Kahn SE. Clinical review 135: the importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047-4058.
53. Stern MP. Strategies and prospects for finding insulin resistance genes. J Clin Invest. 2000;106:323-327.
54. Vaag A. On the pathophysiology of late onset non-insulin dependent diabetes mellitus: current controversies and new insights. Dan Med Bull. 1999;46:197-234.
55. Alper J. Biomedicine: new insights into type 2 diabetes. Science. 2000;289:37-39.
56. Kahn CR, Brüning JC, Michael MD, Kulkarni RN. Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes mellitus, J Pediatr Endocrinot Metab. 2000;13(suppl 6):1377-1384.
57. McIntyre EA, Walker M. Genetics of type 2 diabetes and insulin resistance: knowledge from human studies. Clin Endocrinot (Oxf). 2002;57:303-311.
58. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus [published correction appears in Nat Genet. 2000;26:502]. Nat Genet. 2000;26:163-175.
59. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76-80.
60. Stumvoll M, Häring H. The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism. Diabetes. 2002;51:2341-2347.
61. Cox NJ. Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: examples from studies of the calpain-10 gene. Hum Mol Genet. 2001;10:2301-2305.
62. Bergman RN, Ader M. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab. 2000;11:351-356.
63. Boyko EJ, Fujimoto WY, Leonetti DL, Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: a prospective study among Japanese Americans. Diabetes Care. 2000;23:465-471.
64. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108(suppl 6a):9S-14S.
65. Banerji MA, Chaiken RL, Gordon D, Kral JG, Lebovitz HE. Does intra-abdominal adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes. 1995;44:141-146.
66. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes. 1996;45:633-638.
67. Bak JF, Möller N, Schmitz O, Saaek A, Pedersen O. In vivo insulin action and muscle glycogen synthase activity in type 2 (non-insulin-dependent) diabetes mellitus: effects of diet treatment. Diabetologia. 1992;35:777-784.
68. Beck-Nielsen H, Pedersen O, Lindskov HO. Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol (Copenh). 1979;90:103-112.
69. Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus: effect of weight loss. J Clin Invest. 1988;82:1398-1406.
70. Long SD, O'Brien K, MacDonald KG Jr, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes: a longitudinal interventional study. Diabetes Care. 1994;17:372-375.
71. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537-544.
72. Knowler W, Barrett-Connor E, Fowler SE, et al, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
73. Tuomilehto J, Lindström J, Eriksson J, et al, Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
74. Boden G. Free fatty acids, insulin resistance, and type 2 diabetes mellitus. Proc Assoc Am Physicians. 1999;111:241-248.
75. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.
76. Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucosemetabolism. Eur J Pharmacol. 2002;440:213-221.
77. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595-1599.
78. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930-1935.
79. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947-953.
80. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001;50:2094-2099.
81. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941-946.
82. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98:2005-2010.
83. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis [editorial]. Circulation. 2002;105:2696-2698.
84. Nyholm B, Mengel A, Nielson S, Møller N, Schmitz O. The insulin resistance of relatives of type 2 diabetic subjects is significantly related to a reduced VO2 max [abstract]. Diabetologia. 1994;37(suppl 1):A28. Abstract 104.
85. Swinburn BA. Effect of dietary lipid on insulin action: clinical studies. Ann N Y Acad Sci. 1993;683:102-109.
86. Pandit MK, Burke J, Gustafson AB,Minocha A, Peiris AN. Drug-induced disorders of glucose tolerance. Ann Intern Med. 1993; 118:529-539.
87. Yki-Jarvinen H. Glucose toxicity. Endocr Rev. 1992;13:415-431.
88. Bonora E, Bonadonna RC, Del Prato S, et al. In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension. Diabetes. 1993;42:764-772.
89. Campbell PJ, Mandarino LJ, Gerich JE. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism. 1988;37:15-21.
90. Groop LC, Widén E, Ferrannini E. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods? Diabetologia. 1993;36:1326-1331.
91. Kalant N, Leibovici D, Fukushima N, Kuyumjian J, Ozaki S. Insulin responsiveness of superficial forearm tissues in type 2 (non-insulin dependent) diabetes. Diabetologia. 1982;22:239-244.
92. Nosadini R, Solini A, Velussi M, et al. Impaired insulin-induced glucose uptake by extrahepatic tissue is hallmark of NIDDM patients who have or will develop hypertension and microalbuminuria. Diabetes. 1994;43:491-499.
93. Burks DJ, White MF. IRS proteins and β-cell function. Diabetes. 2001;50(suppl 1):S140-S145.
94. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest. 2000;106:329-333.
95. Kahn SE. The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108(suppl 6a):2S-8S.
96. Porte D Jr. β-Cells in type II diabetes mellitus. Diabetes. 1991;40:166-180.
97. Karam JH, Forsham PH. Pancreatic hormones and diabetes mellitus. In: Greenspan FS, Baxter JD, eds. Basic and Clinical Endocrinology. 4th ed. Norwalk, Conn: Appleton & Lange; 1994:571-634.
98. Gin H, Rigalleau V. Post-prandial hyperglycemia and diabetes. Diabetes Metab. 2000;26:265-272.
99. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes. 1993;42:1663-1672.
100. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia. 2001;44:929-945.
101. van Haeften TW, Pimenta W, Mitrakou A, et al. Relative contributions of β-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism. 2000;49:1318-1325.
102. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981;68:1456-1467.
103. Bouchard C. Genetics and the metabolic syndrome. Int J Obes Relat Metab Disord. 1995;19(suppl 1):S52-S59.
104. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC, UK Prospective Diabetes Study (UKPDS) Group. UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med. 1998;15:297-303.
105. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med. 1998;15:290-296.
106. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
107. Gray A, Raikou M, McGuire A, et al, United Kingdom Prospective Diabetes Study Group. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). BMJ. 2000;320:1373-1378.
108. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44:2107-2114.
109. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233-240.
110. Haffner SM. The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev. 1998;19:583-592.
111. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Subclinical states of glucose intolerance and risk of death in the U.S. Diabetes Care. 2001;24:447-453.
112. Gerstein HC. Fasting versus postload glucose levels: why the controversy? [editorial]. Diabetes Care. 2001;24:1855-1857.
113. Cook JT, Page RC, Levy JC, Hammersley MS, Walravens EK, Turner RC. Hyperglycaemic progression in subjects with impaired glucose tolerance: association with decline in beta cell function. Diabet Med. 1993;10:321-326.
114. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326:22-29.
115. Swinburn BA, Gianchandani R, Saad MF, Lillioja S. In vivo β-cell function at the transition to early non-insulin-dependent diabetes mellitus. Metabolism. 1995;44:757-764.
116. Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes. 2002; 51(suppl 1):S109-S116.
117. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes. 1988;37:736-744.
118. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16: Overview of 6 years' therapy of type II diabetes: a progressive disease [published correction appears in Diabetes. 1996;45:1655]. Diabetes. 1995;44:1249-1258.
119. Turner RC, Cull CA, Frighi V, Holman RR, UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005-2012.
120. Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc. 2003;78:459-467.
121. Zangeneh F, Kudva YC, Basu A. Insulin sensitizers. Mayo Clin Proc. 2003;78:471-479.